8-K: Claritev Corporation Reports Q1 2026 Financial Results

Claritev Corporation announced its first quarter 2026 financial results, reporting revenue growth and an increase in Adjusted EBITDA, while also detailing a net loss and increased cash used in operations.

Summary

• Claritev Corporation reported first quarter 2026 revenues of $244.7 million, a 5.8% increase compared to $231.3 million in the first quarter of 2025.
• The company reported a net loss of $73.6 million for Q1 2026, an increase from the $71.3 million net loss in Q1 2025.
• Adjusted EBITDA for Q1 2026 was $146.9 million, up 3.4% from $142.1 million in Q1 2025, though the Adjusted EBITDA margin decreased slightly to 60.0% from 61.4%.
• Net cash used in operating activities was $45.8 million in Q1 2026, compared to $30.1 million used in Q1 2025.
• Free Cash Flow for Q1 2026 was $(92.5) million, a wider deficit than the $(68.9) million in Q1 2025.
• The company ended Q1 2026 with $21.3 million in unrestricted cash and cash equivalents.
• Full-year 2026 revenue guidance was updated to $985 million to $1 billion, a slight increase from the previous guidance of $980 million to $1 billion.
• Full-year 2026 Adjusted EBITDA guidance remains $605 million to $615 million, and Free Cash Flow guidance remains $0 million to $10 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but cautiously optimistic report, with positive revenue and Adjusted EBITDA growth offset by a widening net loss and increased cash burn from operations.

Positives

• Revenue increased by 5.8% to $244.7 million in Q1 2026 compared to Q1 2025.
• Adjusted EBITDA increased by 3.4% to $146.9 million in Q1 2026 compared to Q1 2025.
• The company's Q1 2026 bookings performance was strong, driven by core offerings and significant wins in the provider and government verticals, indicating revenue stream diversification.
• Full-year 2026 revenue guidance was slightly increased to a range of $985 million to $1 billion.
• The company's Chairman, CEO, and President expressed confidence in the team, growth, and the foundation being built, citing outperformance on top and bottom lines.

Negatives

• Net loss widened to $73.6 million in Q1 2026 from $71.3 million in Q1 2025.
• Net cash used in operating activities increased to $45.8 million in Q1 2026 from $30.1 million in Q1 2025.
• Free Cash Flow deficit widened to $(92.5) million in Q1 2026 from $(68.9) million in Q1 2025.
• Adjusted EBITDA margin decreased to 60.0% in Q1 2026 from 61.4% in Q1 2025.
• Unrestricted cash and cash equivalents were $21.3 million at the end of Q1 2026, a modest increase from $16.8 million at the end of 2025, but still a relatively small buffer given operational cash burn.

Risks

• Loss of, or significant reduction in work for, clients, particularly largest clients.
• Inability to achieve goals of strategic plans and recognize anticipated benefits.
• Challenges in entering new lines of business and broadening solutions.
• Trends in the U.S. healthcare system, including reduced utilization and increased patient financial responsibility.
• Effects of competition and pricing pressure.
• Inability of clients to pay for solutions.
• Changes in industry standards and technology.
• Adverse outcomes in litigation or governmental proceedings.

Future Outlook

The company updated its full-year 2026 guidance, increasing the revenue forecast to $985 million to $1 billion from $980 million to $1 billion. Guidance for Adjusted EBITDA remains $605 million to $615 million, and Free Cash Flow guidance remains $0 million to $10 million.

Management Comments

• "Claritev kicked off 2026 the same way we closed 2025, outperforming on the top and bottom lines with focused execution in sales, operations and financials. We are operating with confidence - confidence in our team, confidence in our growth, and confidence in the durability of the foundation we are building."
• "At our Investor Day in March, we laid out the path and key drivers behind Vision 2030. Simply put, we are matching our horizontal products with an expanding vertical market strategy that serves the entire healthcare lifecycle. Its working and our first quarter performance underscores how the combination of that vision and our competitive position is leading to greater success and faster growth."
• "Our first quarter results demonstrate the consistency and quality of Claritevs core, and the growth opportunities created by our expansion into new markets and verticals."
• "Notably, the strong Q1 bookings performance comes from our core offerings and markets, alongside significant wins in the provider and government verticals, demonstrating the diversification of Claritevs revenue streams and the foundation we are building to deliver sustainable, long term growth."

Industry Context

StockSavvy.ai notes that Claritev's focus on healthcare affordability, transparency, and fairness aligns with ongoing industry pressures and regulatory shifts aimed at controlling healthcare costs. The reported revenue growth and increased Adjusted EBITDA, despite a net loss, suggest the company is navigating these complex market dynamics effectively, particularly with its expansion into provider and government verticals.

Stakeholder Impact

• Shareholders: The widening net loss and increased cash used in operations may be a concern, though revenue growth and updated guidance offer some positive signals.
• Employees: Management expresses confidence in the team and the foundation being built, suggesting a stable operational environment.
• Clients: The company highlights strong client relationships and wins in new verticals, indicating continued service and potential for expanded offerings.
• Providers: Significant wins in the provider vertical suggest positive engagement and partnership development.

Next Steps

• Continue execution of the Vision 2030 transformation program.
• Leverage horizontal products with an expanding vertical market strategy.
• Continue to press competitive advantages including client relationships, data ecosystem, domain expertise, and AI application.
• Focus on delivering sustainable, long-term growth through diversified revenue streams.

Key Dates

Recommendation

The company shows positive revenue and Adjusted EBITDA trends, with a slight increase in full-year revenue guidance. However, the widening net loss, increased operational cash burn, and decreased Adjusted EBITDA margin suggest caution. The company is executing on its strategy, but the path to profitability and sustainable free cash flow generation requires further demonstration.

Keywords

Claritev Corporation, Healthcare Technology, Financial Results, Q1 2026, Adjusted EBITDA, Revenue Growth, Net Loss, Form 8-K